EGFR and non-small cell lung carcinoma: By contrast, RM-018 had little or no effect on ERK inhibition or the cell growth of A549, a KRASG12S mutant NSCLC cell line or in PC-9, a NSCLC cell line with an EGFR mutation and KRASWT, consistent with the specificity of this inhibitor for KRASG12C (Supplementary Fig. 1c, d).